Definition

A human bispecific antibody, with potential antineoplastic activity. Anti-CD22/CD3 bispecific antibody JNJ-75348780 contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, JNJ-75348780 binds to both CD3 on T cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B cells. CD22 is exclusively expressed on B cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.